ScripsAmerica (SCRC -OTC BB ) provides a strong low cost system of broad base US national marketing, sales and distribution of generic Rx, branded Rx, OTC, nutraceuticals, and oral delivery OTC pharmaceuticals through mass merchants, super markets, chain drug stores, independent drug stores, hospitals, long term care, HMO’s, home health care, clinics, PBM’s, State and Federal Government (Department of Veterans Affairs, Department of Defense).
This strong marketing platform can provide a launch pad for immediately introducing ANDAs for any global company. “Pull Through” network of the Company results in strong customer retention, low cost and access to wide customer base.
The Company has strong relationships with local customers and deep understanding of and ability to serve customer needs. These relationships with ScripsAmerica will allow the Company to acquire asubstantial shelf space for its products in very short span of time.
The Company caters to a large base of customers without carrying substantial inventory. This demonstrates ScripsAmerica’s ability of flawless execution of management in a pure generic market. Going forward, with the increase in the revenue and customer base, the Company is focused on ensuring strict control on its inventory, at the same time achieving minimum turnaround time.
Some people may wish to better understand the economically intelligent practice of generic substitution for branded drugs. We've put this section together to assist in this endeavor. It is taken primarily from the US FDA Office of Generic Drugs website (http://www.fda.gov/cder/ogd) which contains a wealth of additional information for those truly inquisitive minds.
The GphA site (http://www.gphaonline.org) is another excellent source where visitors can learn that "generic drugs contain the same active ingredients, in the very same strength, as brand-name drugs." Stated simply here, "When a medicine is first developed, the pharmaceutical company that discovers and markets it receives a patent on its new drug. The patent usually lasts for 20 years, to give the originating company a chance to recoup its research investment. After the patent expires, a generic version of the drug may become available. Generics are marketed under the drug's chemical, or "generic," name and meet the same U.S. Food and Drug Administration (FDA) quality and effectiveness standards as the original."
According to the US FDA, a generic drug is identical (defined as bio-equivalent) to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use. Although generic drugs' active ingredients are chemically identical to and equally as effective as their branded counterparts, they are typically sold at substantial discounts from the branded price. According to the Congressional Budget Office, generic drugs save consumers an estimated $8-$10 billion a year at retail pharmacies. Even more billions are saved when hospitals use generics.
To Gain FDA approval a generic drug must:
•Contain the same active ingredients as the innovator drug (inactive ingredients may vary)
•Be identical in strength, dosage form and route of administration
•Have the same use indications
•Be bio-equivalent
•Meet the same batch requirements for identity, strength, purity and quality
•Be manufactured under the same strict standards of FDA's good manufacturing practice regulations required for innovator products.
On its site, the GphA states, "With every prescription that you have filled with a generic, you get the same medicine as the brand, with the same quality and same result, but at a much lower cost." So, at the end of the day, generics offer a smart and affordable alternative to branded drug therapies. To learn more, visit one of these excellent sites:
•http://www.fda.gov/cder/ogd
•http://www.gphaonline.org/about-gpha/about-generics
Management
Robert Schneiderman, Chief Executive Officer, Founding Partner
Mr. Schneiderman has an extensive background of accomplishments. His experience includes using his established network to facilitate the financing of public and non public companies and assisting with mergers and acquisitions. His clients have included StarMed Group Inc., Medical Wellness Inc., Direct Pharmacy Services Inc., Aquantum Pharmaceuticals Inc., Coral Water Inc., Radius WellCare Inc., Axis Technology Inc., and Global Resources Inc. He has been involved with marketing and consulting on a vast array of projects. These projects have included expansion of clients’ customer base via product development, placement into mass retail, development of marketing programs, and effectively establishing and maintaining communications between all involved parties.
Mr. Schneiderman brings to ScripsAmerica expertise in implementing marketing strategies, developing advertising-media programs, project management, structuring of operational systems, facilitation of client needs, procedures, expanding marketing channels, liaison between marketing channels-services and clients, as well as contract negotiations.
Mr. Schneiderman has had personnel, operations, financial management and supervisory experience for 32 years as CEO of a prominent Philadelphia recruiting firm. In addition, he has served as committee chairman for charity and community service organizations guiding, advising, recruiting and motivating volunteers and has engaged in hands-on supervision and activity in the areas of fundraising, gala events, special event planning, social event planning, enhancement of membership recruitment procedures, writing of newsletter articles, and speeches. Mr. Schneiderman earned a B.S. in Business from Temple University.
Jeffrey Andrews, Chief Financial Officer
A creative, results-oriented problem solver with a background in financial accounting, Mr. Andrews has served companies in the manufacturing, distribution, technology, consulting, construction, and service industries. His professional experience includes tenure as Chief Financial Officer for Global Resource Corporation, Judge Information Management Solutions, and The Judge Group; Controller of Encapsulation Systems, Goodwin Pumps of America, Morris Wheeler & Co., and Mater Burt Co.; Audit Manager of Stockton Bates/Gold & Co., C.P.A.; and as Manager of Ernst & Young’s Special Services Group.
After joining ScripsAmerica in September 2010, Mr. Andrews took responsibility for the overall financial management of the Company, financial reporting and transparency, and for corporate functions including controller, treasury, investor relations, long-range planning, and corporate and strategic development. Mr. Andrews earned a B.S. in Accounting from Villanova University, is a Certified Public Accountant in the Commonwealth of Pennsylvania, and a member of both the American Institute and the Pennsylvania Institute of Certified Public Accountants.
Wayne Ambler, Director of Marketing
Accomplished, sales and marketing professional with over two decades experience in the competitive store brand OTC health and wellness marketplace. An articulate, reliable, and proven revenue producer adept at assessing prospects capabilities and strengths to create new marketing opportunities for expansion of existing product offerings while pioneering client new growth.
Professional services include direct sales coverage and broker management for store brand OTC companies in all classes of retail trade (FDM)
Assists in product selection, brand marketing, promotional activities, sales tools and website development, specializing in the pharmaceutical industry.
Featured Products and Applications
RapiMed Product Line 
________________________________________________________________________________________________________________
In light of the fact that the ODT market is growing significantly, driven by patient demand, rapid melt technology, provides pharmaceutical companies with the much-needed opportunity for product line extensions for a wide variety of drugs. ScripsAmerica sees a significant opportunity as a contract developer of Quickmelt technology embedded in RapiMed specialty pharmaceuticals.
In March 2010, ScripsAmerica entered into a product development, manufacturing, and supply agreement for Acetaminophen 80mg and 160mg orally disintegrating rapid dissolve tablets under which its partner will develop and supply the product, while ScripsAmerica will fund all development costs and own the final product.
The Company’s initial focus is on Pediatric analgesic 80mg and 160mg orally disintegrating rapid dissolve tablets, which are under development with a market rollout scheduled for Q2 2013. The 80mg and 160mg dosing strength will be particularly applicable to children to solvecommon overdosing or under dosing issues that 2-11-year-olds tend to experience when taking liquid pain relievers or fever reducers in doses intended for adults.
Safely administering liquids such as Children’s Tylenol Suspension to children requires precise dosage measurement in increments of half a teaspoon, depending on the child’s weight or age. Inadvertent overdosing – whether by an adult’s error or perhaps a child’s self-administration - may lead to severe liver damage and requires immediate medical attention even in the absence of signs or symptoms. Conversely, ODTs such as ScripsAmerica’s Pediatric RapiMed represent a precise, standardized dose in the form of discrete, easy-to-count, individually blister-packaged tablets, thereby reducing the probability of human error while the drug is being administered. Finally, the taste of ODTs can easily be tailored to appeal to children, using a variety of flavored coatings.
ScripsAmerica’s Pediatric “RapiMed” will compete with other children’s analgesic products, such as Johnson & Johnson’s Children’s Tylenol Suspension Liquid and Children’s Tylenol Meltaways, Novartis’ Triaminic Fever Reducer Pain Reliever, and Perrigo’s Junior Strength Non-Aspirin Suspension Liquids & Drugs. According to Euromonitor International’s research, J&J’s Children’s Tylenol sales represented 23% of global and 76% of U.S. retail value sales in child-specific analgesics. Global sales were valued at $695 million in 2009.
ScripsAmerica anticipates project completion with market rollout scheduled for 2013.
RapiMed formulation is compatible for use in the development of Oral Delivery Technology products to treat Migraines, Sleep Deprivation, Allergies, and Vitamin Deficiencies more lat night
| Ticker Symbol: SCRCQ |
| Outstanding Shares: 137M in which just Three owners hold 79% of Entire OS! |
Floating Shares: 80M in which only a few millions shares available for trading!
Shareholders:103 Funding to Date:2.5 Mil
Preferred Convertible: $1.1 mil @ .175
Convertible Debt: 975k @ .25
Other: 453K @ 4 Year Term
Shares Structure: Delaware Corp |
WEB SITE http://scripsamerica.com/
Updated Date: 2019-03-19T14:28:17Z Creation Date: 2008-04-29T23:35:56Z Registrar Registration Expiration Date: 2020-03-18T11:59:59Z